BeyondSpring Inc.

BYSI | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.74

$0 (0.00%)

At close: Sep 22, 2026, 4:00 PM ET

$0.75

+$0.01 (+0.85%)

After-hours: Sep 22, 2026, 5:11 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

Rating

Updated: Aug 28, 2026

24.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $30.44M

1D Range

0.73 0.76

52W Range

0.57 2.44

Valuation (TTM)

PE -4.35

PB -0.86

EV/EBITDA -3.02

Valuation (NTM)

Forward PE 0.86

Forward PEG -0.06

Price Target N/A

Cash Flow

FCF Yield -55.8%

SBC Adj. FCF Yield -59.3%

SBC Impact -6.1%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -321.2% | -69.5%

Dil EPS 3Y | 5Y 54.1% | 53.4%

FCF 3Y | 5Y -93.1% | -17.5%

Returns

ROA -45.8%

ROE 20.0%

ROIC -1429.6%

Financial Health

Net Cash

$6.36M

Current Ratio 0.70

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding...

Sector Healthcare

Industry Biotechnology

Employees 44

IPO Date Mar 8, 2017

Website www.beyondspringpharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞